{"product_id":"alcohol-and-drug-misuse-9780470659694","title":"Alcohol and Drug Misuse","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eThere is constant pressure for clinicians to practise evidence-based medicine. Cochrane Reviews are an important source of the evidence which informs clinical decisions but can still require considerable time to read and digest. This \u003ci\u003eCochrane Handbook of Alcohol and Drug Misuse\u003c\/i\u003e serves as a concise guide to the evidence base for relevant interventions, highlighting the key points of Cochrane reviews for the busy practitioner.\u003c\/p\u003e \u003cp\u003eEach review is analysed in a structured format, starting with the question, a brief background and a summary answer, followed by the results presented in comprehensive and concise way. The authors then illustrate the value that the review adds to the current knowledge, the main methodological limitations of the included studies and finally the implications of the review's conclusions for future research.\u003c\/p\u003e \u003cp\u003eAddiction to drugs and alcohol is an increasing problem that all clinicians have to deal with. This is especially true for medical and fami\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\"Overall the book is a well written, engaging, comprehensive guide to Psychiatry. It is a good beginner’s guide to the practice of psychiatric medicine because it packs relevant information into a tightly condensed bundle.\" (\u003ci\u003e\u003cb\u003eAsian Journal of Psychiatry, 2013)\u003c\/b\u003e\u003c\/i\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003eForeword, ix\u003c\/p\u003e \u003cp\u003ePreface, xi\u003c\/p\u003e \u003cp\u003eAcknowledgements, xii\u003c\/p\u003e \u003cp\u003ePart 1: Alcohol\u003c\/p\u003e \u003cp\u003ePsychosocial interventions\u003c\/p\u003e \u003cp\u003eChapter 1: Effectiveness of brief alcohol interventions in primary care populations, 1\u003c\/p\u003e \u003cp\u003eChapter 2: Brief interventions for heavy alcohol users admitted to general hospital wards, 5\u003c\/p\u003e \u003cp\u003eChapter 3: Alcoholics Anonymous and other 12-step programmes for alcohol dependence, 8\u003c\/p\u003e \u003cp\u003eChapter 4: Mentoring adolescents to prevent substance use disorders, 10\u003c\/p\u003e \u003cp\u003eChapter 5: Universal school-based prevention programmes for alcohol misuse in young people, 12\u003c\/p\u003e \u003cp\u003eChapter 6: Universal multicomponent prevention programmes for alcohol misuse in young people, 15\u003c\/p\u003e \u003cp\u003eChapter 7: Universal family-based prevention programmes for alcohol misuse in young people, 17\u003c\/p\u003e \u003cp\u003eChapter 8: Social norms interventions to reduce alcohol misuse in university or college students, 19\u003c\/p\u003e \u003cp\u003eChapter 9: Psychosocial interventions for women enrolled in alcohol treatment during pregnancy, 22\u003c\/p\u003e \u003cp\u003ePharmacological interventions\u003c\/p\u003e \u003cp\u003eChapter 10: Benzodiazepines for alcohol withdrawal, 24\u003c\/p\u003e \u003cp\u003eChapter 11: Anticonvulsants for alcohol withdrawal, 27\u003c\/p\u003e \u003cp\u003eChapter 12: Acamprosate for alcohol dependence, 31\u003c\/p\u003e \u003cp\u003eChapter 13: Baclofen for alcohol withdrawal, 34\u003c\/p\u003e \u003cp\u003eChapter 14: Gamma-hydroxybutyrate for treatment of alcohol withdrawal and prevention of relapse, 36\u003c\/p\u003e \u003cp\u003eChapter 15: Psychotropic analgesic nitrous oxide for alcohol withdrawal, 40\u003c\/p\u003e \u003cp\u003eChapter 16: Efficacy and safety of pharmacological interventions for the treatment of alcohol withdrawal, 43\u003c\/p\u003e \u003cp\u003eChapter 17: Opioid antagonists for alcohol dependence, 46\u003c\/p\u003e \u003cp\u003eChapter 18: Pharmacologic interventions for pregnant women enrolled in alcohol treatment, 49\u003c\/p\u003e \u003cp\u003ePart 2: Drugs\u003c\/p\u003e \u003cp\u003ePsychosocial interventions\u003c\/p\u003e \u003cp\u003eChapter 19: School-based prevention for illicit substance use disorders, 51\u003c\/p\u003e \u003cp\u003eChapter 20: Interventions for prevention of substance use disorders by young people delivered in non-school settings, 54\u003c\/p\u003e \u003cp\u003eChapter 21: Case management for persons with substance use disorders, 56\u003c\/p\u003e \u003cp\u003eChapter 22: Motivational interviewing for substance use disorders, 59\u003c\/p\u003e \u003cp\u003eChapter 23: Therapeutic communities for substance use disorders, 62\u003c\/p\u003e \u003cp\u003eChapter 24: Interventions for drug-using offenders in the courts, secure establishments and the community, 64\u003c\/p\u003e \u003cp\u003eChapter 25: Psychosocial interventions for pregnant women in outpatient illicit drug treatment programmes compared to other interventions, 67\u003c\/p\u003e \u003cp\u003eCocaine dependence\u003c\/p\u003e \u003cp\u003eChapter 26 Psychosocial interventions for cocaine and psychostimulant amphetamine related disorders, 69\u003c\/p\u003e \u003cp\u003eChapter 27: Antidepressants for cocaine dependence, 71\u003c\/p\u003e \u003cp\u003eChapter 28: Antipsychotic medications for cocaine dependence, 74\u003c\/p\u003e \u003cp\u003eChapter 29: Anticonvulsants for cocaine dependence, 76\u003c\/p\u003e \u003cp\u003eChapter 30: Dopamine agonists for cocaine dependence, 78\u003c\/p\u003e \u003cp\u003eChapter 31: Disulfiram for the treatment of cocaine dependence, 82\u003c\/p\u003e \u003cp\u003eChapter 32: Efficacy of psychostimulant drugs for cocaine dependence, 84\u003c\/p\u003e \u003cp\u003eChapter 33: Auricular acupuncture for cocaine dependence, 87\u003c\/p\u003e \u003cp\u003eChapter 34: Psychosocial treatment for opiate dependence, 89\u003c\/p\u003e \u003cp\u003eChapter 35: Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification, 91\u003c\/p\u003e \u003cp\u003eChapter 36: Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence, 94\u003c\/p\u003e \u003cp\u003eChapter 37: Alpha withdrawal, 96\u003c\/p\u003e \u003cp\u003eChapter 38: Buprenorphine for the management of opioid withdrawal, 99\u003c\/p\u003e \u003cp\u003eChapter 39: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence, 102\u003c\/p\u003e \u003cp\u003eChapter 40: Methadone at tapered doses for the management of opioid withdrawal, 105\u003c\/p\u003e \u003cp\u003eChapter 41: Methadone maintenance at different dosages for opioid dependence, 108\u003c\/p\u003e \u003cp\u003eChapter 42: Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence, 110\u003c\/p\u003e \u003cp\u003eChapter 43: Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal, 113\u003c\/p\u003e \u003cp\u003eChapter 44: Opioid antagonists with minimal sedation for opioid withdrawal, 115\u003c\/p\u003e \u003cp\u003eChapter 45: Oral naltrexone maintenance treatment for opioid dependence, 118\u003c\/p\u003e \u003cp\u003eChapter 46: Sustained-release naltrexone for opioid dependence, 121\u003c\/p\u003e \u003cp\u003eChapter 47: Heroin maintenance for chronic heroin-dependent individuals, 123\u003c\/p\u003e \u003cp\u003eChapter 48: LAAM maintenance versus methadone maintenance for heroin dependence, 126\u003c\/p\u003e \u003cp\u003eChapter 49: Detoxification treatments for opiate-dependent adolescents, 129\u003c\/p\u003e \u003cp\u003eChapter 50: Maintenance treatments for opiate-dependent adolescents, 131\u003c\/p\u003e \u003cp\u003eChapter 51: Maintenance agonist treatments for opiate-dependent pregnant women, 133\u003c\/p\u003e \u003cp\u003eChapter 52: Pharmacological treatment for depression during opioid agonist treatment for opioid dependence, 135\u003c\/p\u003e \u003cp\u003eChapter 53: Inpatient versus other settings for detoxification for opioid dependence, 138\u003c\/p\u003e \u003cp\u003eChapter 54: Psychotherapeutic interventions for cannabis use or dependence in outpatient settings, 140\u003c\/p\u003e \u003cp\u003eChapter 55: Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings, 142\u003c\/p\u003e \u003cp\u003eChapter 56: Treatment for amphetamine dependence, 145\u003c\/p\u003e \u003cp\u003eChapter 57: Treatment for amphetamine withdrawal, 147\u003c\/p\u003e \u003cp\u003eChapter 58: Treatment for amphetamine psychosis, 149\u003c\/p\u003e \u003cp\u003eChapter 59: Treatment for methaqualone dependence in adults, 151\u003c\/p\u003e \u003cp\u003eIndex, 153\u003c\/p\u003e","brand":"John Wiley and Sons Ltd","offers":[{"title":"Default Title","offer_id":49402394706263,"sku":"9780470659694","price":37.95,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780470659694.jpg?v=1730480266","url":"https:\/\/bookcurl.com\/products\/alcohol-and-drug-misuse-9780470659694","provider":"Book Curl","version":"1.0","type":"link"}